Amyloid-␤ and Alzheimer Disease: The Null Hypothesis
A wealth of evidence implicates amyloid-␤ (A␤) in the pathogenesis of Alzheimer disease (AD), leading to the formulation of the amyloid cascade hypothesis (Fig. 1) , i.e., the null hypothesis (Hardy and Higgins, 1992; Hardy, 2006) . Casual observation of post mortem brain tissue of affected individuals makes it quite obvious why A␤ is the primary suspect in disease pathogenesis, because A␤ is the major constituent in two of the most distinctive histopathologies, namely senile plaques and cerebral amyloid angiopathy (Glenner and Wong, 1984a,b; Masters et al., 1985) . The destruction surrounding A␤ is evident from a close examination of histological preparations in the immediate vicinity of senile plaques and amyloid angiopathy, respectively, where degenerative neuronal processes and smooth muscle cells surrounding and infiltrating the A␤ deposits are found, respectively (Geddes et al., 1986; Kawai et al., 1992) . Furthermore, areas that are severely affected by disease, namely the hippocampal and frontotemporal cortices, show colocalization between A␤ plaques and neuronal cell death (Rogers and Morrison, 1985) . Investigators have explored whether A␤ is toxic to neurons in both in vitro culture assays and in the intact brain of animals. Initially, results of these experiments were extremely inconsistent, stemming from variability among commercial preparation of the peptide and the lack of proper control over whether A␤ was aggregated into fibrils of ␤-sheet conformation (Cotman et al., 1992) . However, it is now firmly established that fibrillation of A␤ is needed to obtain neurotoxic effects (Pike et al., 1993; Lorenzo and Yankner, 1996; Yankner, 1996) and that, under many circumstances, such fibrils are inherently toxic to both neurons and clonal cell lines in culture (Yankner et al., 1990; Pike et al., 1991) . The neurotoxicity of A␤ peptide in vivo was likewise measured by infusion of the peptide to various animal models. Notably, intracortical injection of A␤ 1-42 or A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] fragments into aged rats or primates produced lesions that looked like those found in AD patients (Kowall et al., 1992) .
The source of A␤ toxicity still remains elusive, regardless of the proliferation of theories advanced. The first theory proposed advocated interactions with cell surface receptors triggering an intracellular signaling cascade, but little experimental evidence has supported this hypothesis. On the other hand, studies have long since supported the idea that oxidative event(s) are crucial for A␤ toxicity (reviewed by Mattson, 1995) , such that A␤ peptide is capable of generating reactive oxygen species (ROS) through the generation of hydrogen peroxide (Hensley et al., 1994; Huang et al., 1999a,b) and of stimulating inflammatory cells (Meda et al., 1995; Butterfield et al., 1996; Van Muiswinkel et al., 1996; Akama et al., 1998) . The significance of reactive oxygen in A␤ toxicity is attested by the attenuation of toxicity by administration of antioxidants as well as free radical scavengers, such as vitamin E (Behl et al., 1992) . This pro-oxidant view of A␤ is further supported by in vivo evidence where deposits are associated with oxidative damage (Smith et al., , 1998 Atwood et al., 2002) , and such damage, like A␤ deposition (Selkoe, 1999) , is viewed as an early event in disease pathogenesis (Nunomura et al., 1999 . However, while it is clear that A␤ directly or indirectly promotes oxidative stress and that such toxicity can be attenuated by antioxidants, the precise mechanism that connects amyloid deposition to increased oxidative stress is not yet resolved. For example, while multiple studies have suggested that the neurotoxicity of aggregated A␤ is mediated by its ability to induce oxidative stress through spontaneous generation of free radicals and ROS (Hensley et al., 1994) , this proposition has been called into question on both theoretical and experimental grounds Dikalov et al., 1999; Turnbull et al., 2001) , and it now seems that the oxidant effects of A␤ are mediated by its interaction with redox-active metals such as iron and copper because chelation of A␤ significantly attenuates toxicity . A␤ has an unusually high affinity for both iron and copper (Huang et al., 1997; Atwood et al., 1998; Cuajungco et al., 2000) and can reduce these metals with the subsequent production of H 2 O 2 and oxidized amyloid (Huang et al., 1999a,b) . The relevance of this mechanism to disease pathogenesis is highlighted by the association of redox active metals with senile plaques in AD Sayre et al., 2000) . In addition, the deposition of this normally soluble cellular protein promotes a chronic inflammatory response in AD, whereby activated microglia release ROS as part of the respiratory burst (reviewed in Atwood et al., 2001 ).
The strongest evidence for the crucial role played by A␤ in AD pathogenesis has been the characterization of the mutations that underlie familial early onset cases of the disease. All of these inherited mutations directly or indirectly affect both the processing and accumulation of A␤. Familial Alzheimer disease (FAD) is associated with point mutations in amyloid-␤ protein precursor (A␤PP) in regions that are involved in the proteolytic processing of the peptide (Goate et al., 1991; Lendon et al., 1997) . It is thought that these mutations accelerate the onset of AD into the fourth decade by increasing the ratio of A␤ 1-42 /A␤ 1-40 , thereby increasing the relative amount of the more fibrillogenic form (Suzuki et al., 1994) . A double mutation at positions 670/671 (Swedish mutation) increases the production of total A␤ and thereby increases the load of A␤ 1-42 without changing the relative ratio (Citron et al., 1992; Cai et al., 1993) . The fact that an increase in total A␤ load accelerates the deposition of A␤ is supported by the neuropathology seen in patients with Down syndrome, a disorder caused by trisomy of chromosome 21, where the A␤PP gene is localized. It is thought that the overexpression of A␤PP in these individuals (Greenberg et al., 1996) causes the formation of A␤ plaques very similar to those seen in AD. The most common form of FAD is caused by mutations in one of the two presenilin genes (PS1 on chromosome 14 or PS2 on chromosome 1) (reviewed by Gooch and Stennett, 1996) . Recently, PS has been identified as one of the component of ␥-secretase, and FAD mutations increase the activity of ␥-secretase, although the alternate roles of PS other than ␥-secretase (Haass and Steiner, 2002) in AD pathogenesis have been suggested as well (Herms et al., 2003; Tu et al., 2006) . Most importantly however, missense mutations in the presenilin genes increase the ratio of A␤ 1-42 /A␤ 1-40 (Citron et al., 1997; Tomita et al., 1997) . Finally, one allele of the apolipoprotein E gene, namely apolipoprotein 4, predisposes individuals to the development of late-onset AD (Corder et al., 1993) . Of the three alleles (also including apolipoproteins 2 and 3), apolipoprotein 4 has the greatest affinity for A␤, is found associated with senile plaques, and is thought to accelerate fibrillogenesis (Wisniewski et al., 1994) . Interestingly, apolipoprotein 2 inhibits fibril formation and is protective against the development of AD (Corder et al., 1994) .
The above evidence implicating A␤ in AD pathogenesis led to the supposition that generation of transgenic animals that either overexpress A␤PP or a mutation in A␤PP that affects processing of the full length protein, thereby leading to an increase in the A␤ 1-42 /A␤ 1-40 ratio, may mimic the pathophysiology that is seen in AD. Taken as a group, the various transgenic mice strains that have been produced thus far have demonstrated that overexpression of mutated A␤PP, but not wild-type A␤PP or overproduction of the A␤ 1-42 peptide fragment, is alone sufficient to cause deposition of the peptide into senile plaque-like structures (reviewed by Holscher, 1998) . Indeed, despite the fact that each of the different constructs yielded somewhat different phenotypes, some aspect of AD pathophysiology is apparent in each of them. For example, Games and colleagues created a transgenic mouse expressing human A␤PP with the V717F mutation at 10 times the endogenous level; these animals developed A␤ plaques in the hippocampus, cerebral cortex, and corpus collosum by 6 to 9 months of age and also showed synaptic loss and astrocytosis (Rogers and Morrison, 1985) . Another popular model is Tg2576 mouse, which overexpresses A␤PP con- taining the Swedish double mutation K670N/M671L. In addition to a marked increase in levels of A␤ in the cerebral spinal fluid and deposition of amyloid plaques, these mice demonstrated marked deficits in spatial learning, as demonstrated by the Morris water maze test, by the age of 9 months (Hsiao et al., 1996) . Even though no neurotoxicity was observed in these mice, it is thought that their impaired spatial learning, which is correlated with long-term potentiation (a model for memory), is related to synaptic loss. Interestingly, these mice also display oxidative stress in association with the plaques, much like that seen in AD (Smith et al., 1998) . Neurodegenerative phenotypes have also been seen, accompanied by an increased mortality rate with 50% of mice dying by 12 months of age compared with an average of 24 months in controls, in mice overexpressing A␤PP (LaFerla et al., 1995) . Although there are differences in the details of these studies, it is clear that A␤ can independently cause ADrelated pathology and some behavioral defects, which mimic AD pathology to a limited extent. Taken together, the above evidence has led many to view A␤ as being the pivotal, if not the sole, culprit for causing disease.
Amyloid-␤ and Alzheimer Disease: The Alternate Hypothesis
The first and foremost argument that A␤ is not the initiator of AD is that deposition of A␤ into senile plaques is by no means specific to AD patients and is instead a marker of normal aging (Davies et al., 1988) . Therefore, the strong association of A␤ in AD may simply mark an acceleration of age-related deterioration. Support for this view can be found with the number of plaques in cognitively normal individuals rivaling those seen in advanced disease (Mann et al., 1992; Schmitt et al., 2000) . Furthermore, there exists only a weak correlation between the burden of A␤ and neuronal loss or cognitive impairment (Giannakopoulos et al., 2003; Guillozet et al., 2003) . Furthermore, increased A␤ production and deposition are also seen as a response to injury in the central nervous system, especially following ischemia and head trauma (Gentleman et al., 1993; Roberts et al., 1994; Geddes et al., 1997) . A␤ deposition in aging and following injury might be a compensation for the primary insult (Lee et al., 2004b) . This is not to imply that, in attempting to respond to cellular stresses, A␤ cannot lead to cellular destruction. However, it does require an underlying pre-existing stress, i.e., the presumptive etiology of AD.
A review of the literature would indicate that the underlying stress is of energetic origin, because a shortage of energy supply [and Ca(II) overload] induces an up-regulation of A␤PP expression. Ischemia, hypoglycemia, and traumatic brain injury, a condition that has been shown to put neurons under metabolic stress (Xiong et al., 1997) , all up-regulate A␤PP and its mRNA in animal models and culture systems (Hall et al., 1995; Jendroska et al., 1995; Yokota et al., 1996; Shi et al., 1997; Murakami et al., 1998) . Not only does energy deficiency and Ca(II) dysregulation promote A␤PP expression, they also route the metabolism of A␤PP from the nonamyloidogenic to the amyloidogenic pathway. For example, loss of mitochondrial energy metabolism alters the processing of A␤PP to generate amyloidogenic derivatives (Gabuzda et al., 1994; Mattson and Pedersen, 1998) , and likewise, oxidative stress increases the generation of A␤ (Frederikse et al., 1996; Neve and Robakis, 1998; Paola et al., 2000) . This finding can be applied to the role of A␤PP as an acute-phase reactant that is up-regulated in neurons, astrocytes, and microglial cells in response to inflammation and numerous associated cellular stresses, including axonal injury (Gentleman et al., 1993; Blumbergs et al., 1995) , loss of innervation (Wallace et al., 1993) , excitotoxic stress (Topper et al., 1995; Panegyres, 1998) , heat shock (Ciallella et al., 1994) , oxidative stress (Yan et al., 1994; Frederikse et al., 1996) , aging (Higgins et al., 1990; Nordstedt et al., 1991; van Gool et al., 1994) , and inflammatory processes (Brugg et al., 1995) . Other proinflammatory stimuli that mediate the synthesis and release of A␤PP include IL-1␤ (Goldgaber et al., 1989; Buxbaum et al., 1992) and tumor necrosis factor-␣-converting enzyme (Buxbaum et al., 1998) . The increased expression of A␤PP by these stresses is probably a result of diminished energy resources. It is interesting that A␤ can regulate glucose metabolism (Ling et al., 2002) and that ␤ islet cells of the pancreas express A␤PP and several related enzymes at high levels (Figueroa et al., 2001) .
The increased generation of A␤ under conditions of energetic stress may therefore be both a response to oxidative challenge observed in AD and following injury as well as a re-routing of metabolic priorities. In this scenario, A␤ in fact plays a protective role. The A␤ burden of the brain negatively correlates with oxidative stress markers (Nunomura et al., 1999 Cuajungco et al., 2000) . This argues against the neurotoxic role of A␤ in vivo, as does the observation that cultured neurons can be cultured directly on top of isolated A␤ plaques or immobilizing A␤ without any notable toxicity (Canning et al., 1993; Carpenter et al., 1993; DeWitt et al., 1998) . Perhaps the in vitro toxicity that is sporadically shown in culture and very unreliable reproduced in animal models may not be an intrinsic property of the peptide itself . Notably, A␤ appears to attenuate oxidative stress in vivo by probably acting as an antioxidant (Cuajungco et al., 2000) . Furthermore, at nanomolar concentrations, A␤ can serve as a trophic factor (Yankner et al., 1990) and attenuates metal-induced oxidative damage (Zou et al., 2002) . These findings are consistent with the trophic and neuroprotective action of A␤ at physiological concentrations (Whitson et al., 1989 (Whitson et al., , 1990 Yankner et al., 1990; Koo et al., 1993; Singh et al., 1994; Luo et al., 1996) . A␤ also protects neurons from death following injection with saline or iron (Bishop and Robinson, 2003) and protects lipoproteins from oxidation in cerebrospinal fluid and plasma (may involve metal ion sequestration) (Atwood et al., 1998; Kontush et al., 2001 ). Moreover, low concentrations of A␤ possess significant antioxidant activity in an ascorbatestimulated-lipid-peroxidation assay (Andorn and Kalaria, 2000) . In summary, the physiological explanation for increased generation of A␤ in AD and following head trauma is the need to reduce ROS to prevent neuronal apoptosis and to promote neuritic repair.
Neurons are especially prone to oxidative stress due to high oxygen consumption, low levels of classic antioxidants, high unsaturated lipid content of neuronal membranes, and lack of mitotic renewal. As a result, the ratio between ROS formation and antioxidant defenses are essential for proper neuronal function. Normally antioxidant defense systems are sufficient to block ROS-mediated damage. However, in cases of age-related neurodegeneration, where there is considerAmyloid-␤ Toxicity-Null and Alternate Hypotheses 825 at ASPET Journals on October 18, 2017 jpet.aspetjournals.org able redox imbalance, oxidative stress overwhelms the system (Zhu et al., 2005) . Given that A␤ is associated with the production of free radicals in vitro, it is essential to consider the in vivo temporal relationship between oxidative stress phenomena and A␤ deposition. Notably, oxidative stress, in vivo, is found in morphologically normal neurons in AD and seems to be inversely correlated with A␤ deposition (Nunomura et al., 1999 . Therefore, it therefore seems unlikely that A␤ accumulation, in vivo, by itself is sufficient to explain altered oxidative balance.
The strongest evidence for the role of A␤ in AD comes from the familial forms of this disease and involves mutations of genes that are directly involved in A␤PP processing. Although a tremendous amount of effort has been dedicated to determining the mechanism of disease related to these mutations, this has proven only marginally useful to our understanding of sporadic AD, which represents the majority of cases. For example, A␤PP mutations have been identified in only 20 to 30 families worldwide and represent far less than 0.1% of the 15 million known cases of AD (Josefson, 2002; Lleo et al., 2004; Hardy and Crook, 2005) . Mutations in both presenilin 1 and 2, which are the most common genetic determinants of AD, only contributes an additional 120 to 130 families. Although it is clear that mutations in these proteins involved in A␤PP processing are capable of inducing amyloid deposition and dementia, no aberrant change is observed usually for many decades, and even then, this is likely a result of exacerbation of age-related deposition of A␤ in these individuals (the joint result of increased A␤ concentration and microenvironmental conditions), leading to the chronic neuroinflammation associated with the disease.
The positive correlation between apolipoprotein E 4 genotype and incidence of AD in supporting a causative role for A␤ is flawed. Although it is true that apolipoprotein E 4 has the greatest affinity for A␤, is found associated with senile plaques, and is thought to accelerate fibrillogenesis (Wisniewski et al., 1994) , this is not the sole or even the major physiological role of apolipoprotein E proteins. Apolipoprotein E helps to regulate the transport and metabolism of lipids. The level of apolipoprotein E is elevated in response to injury in the peripheral and central nervous system (Horsburgh et al., 2000) and, just like A␤, apolipoprotein E may thus serve a protective role after ischemia or traumatic brain injury by distributing phospholipids and cholesterol to injured neurons (Poirier et al., 1993) . Apolipoprotein E may further protect against oxidative injury and prevent the accumulation of lipid peroxidation end products, such as hydroxynonenal, which are prominent features in AD and acute brain injury . In support of this view, various studies show that patients that are homozygous for apolipoprotein 4 genotype have longer periods of unconsciousness and higher incidence of post-traumatic coma following severe traumatic brain injury (Sorbi et al., 1995; Friedman et al., 1999) . Thus, apolipoprotein 4 predisposes patients for any number of neurodegenerative processes, not specific for AD. Therefore, as in acute injury, apolipoprotein 4 may be associated with a higher incidence of AD because it is less efficient in protecting neurons from the causative insult and therefore may have very little to do with its affinity for A␤.
Recently, the original amyloid cascade hypothesis was subsequently forced to be changed to the oligomeric amyloid cascade hypothesis, because a number of discordant findings disprove the amyloid cascade hypothesis as we discussed above. For example, there is a very weak correlation between A␤ and disease state (Giannakopoulos et al., 2003) with very high A␤ loads often seen in cognitively intact old people (Crystal et al., 1988) . Moreover, transgenic animal models, including Tg2576, with supraphysiological A␤ levels, show little/no neuronal loss (Irizarry et al., 1997a,b) . Despite a relative paucity of solid experimental evidence, oligomeric A␤ has quickly risen to be the new star in the field, seemingly through the momentum of the original hypothesis. Nonetheless, until recently, the pathophysiological identity of oligomeric A␤ was unclear. In this regard, recently, Lesne et al. (2006) showed that A␤*56 (which may be a dodecameric oligomer of A␤) is found in cognitively impaired Tg2576 animals without A␤ plaques, but not in unimpaired animals. A␤*56 correlates with early declines in memory but not later ones (Lesne et al., 2006) , and when isolated and injected into rats, A␤*56 leads to reversible cognitive deficits. Although this is an interesting study that will definitely add fuel to the oligomeric amyloid hypothesis, before we get ahead of ourselves, a few salient aspects bear remembrance. First, different groups have reported that knockout of PS1 (i.e., no A␤ and therefore no A␤*56, either), while attenuating A␤ pathology in A␤PP mutant transgenic mice, does not cure cognitive deficits (Dewachter et al., 2002; Saura et al., 2005) . In fact, that PS1 knockout-A␤PP double transgenic animals lacking A␤ perform worse than single A␤PP animals with A␤ might even indicate that A␤ is beneficial in certain circumstances as we previously indicated Rottkamp et al., 2001; Lee et al., 2004a,b) . In any event, what is clear from this is that cognitive deficits do not relate to A␤ (in any guise, even A␤*56). Furthermore, the study by Galvan et al. (2006) provides another clear example that A␤ is not responsible for the cognitive and pathological changes that stereotypify AD (Lee et al., 2004a (Lee et al., ,b, 2006 . Specifically, introducing an additional mutation to A␤PP mice, that prevents the cleavage of A␤PP by caspase, rescues cognitive and pathological deficits but does not affect A␤ plaques. Although these authors did not specifically address whether A␤*56 was affected, the similarities in other A␤ species would tend to indicate not. Therefore, transgenic manipulations have now clearly demonstrated that cognitive deficits and pathological abnormalities in A␤PP transgenic mice bear no relationship to A␤-both the positive and negative control experiments show this result (i.e., cognitive deficits with no A␤ and rescue of cognitive deficits without change of A␤).
The alternate hypothesis (Fig. 2) is that A␤ simply represents a bystander or a protector rather than the causative factor of disease Lee et al., 2003 Lee et al., , 2004b . Notably, all therapeutic studies that have an effect on A␤ levels in cells or animals have shown extremely poor or no efficacy in subsequent clinical trials. This includes indomethacin (Weggen et al., 2001) , ibuprofen , sulindac sulfide (Weggen et al., 2001 ), a nitric oxide-releasing nonsterodial anti-inflammatory drug (Jantzen et al., 2002) , and estrogen (Zheng et al., 2002) . Clearly, the alternate hypothesis points to greater therapeutic efficacy by directing efforts to the upstream metabolic and oxidative abnormalities that are what led to A␤.
